Abhilasha Karkey1, Guy E Thwaites2,3, Stephen Baker2,3,4. 1. Oxford University Clinical Research Unit - Nepal, Patan Hospital, Kathmandu, Nepal. 2. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. 3. Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford. 4. Department of Medicine, University of Cambridge, Cambridge, UK.
Abstract
PURPOSE OF REVIEW: Increasing antimicrobial resistance in Salmonella Typhi is a serious public health concern, especially in industrializing countries. Here we review recent clinical and laboratory data concerning the evolution of antimicrobial resistance, with particular reference to the emergence resistance against fluoroquinolones, third generation cephalosporins, and azithromycin. RECENT FINDINGS: The last 40 years have witnessed the sequential emergence of resistance to all first-line antimicrobials used in the treatment of S. Typhi infections. Multidrug resistance (MDR), defined by resistance to chloramphenicol, amoxicillin, and co-trimoxazole, emerged in the 1990s, followed rapidly by reduced susceptibility to fluoroquinolones. In the current decade, high-level fluoroquinolone resistance has emerged in south Asia and threatens to spread worldwide. Increasing reliance is now being placed on the activity of third generation cephalosporins and azithromycin, but resistance against these agents is developing. Carbapenems and tigecycline may be alternatives, although clinical data are sparse, and in some settings reversion to chloramphenicol and co-trimoxazole susceptibility is occurring. Therefore, older drugs may yet have a role in the treatment of S. Typhi infections. SUMMARY: Good surveillance, improved diagnostics, more prudent use of antimicrobials, and effective vaccines will all be critical to reducing the burden of disease caused by S. Typhi.
PURPOSE OF REVIEW: Increasing antimicrobial resistance in Salmonella Typhi is a serious public health concern, especially in industrializing countries. Here we review recent clinical and laboratory data concerning the evolution of antimicrobial resistance, with particular reference to the emergence resistance against fluoroquinolones, third generation cephalosporins, and azithromycin. RECENT FINDINGS: The last 40 years have witnessed the sequential emergence of resistance to all first-line antimicrobials used in the treatment of S. Typhi infections. Multidrug resistance (MDR), defined by resistance to chloramphenicol, amoxicillin, and co-trimoxazole, emerged in the 1990s, followed rapidly by reduced susceptibility to fluoroquinolones. In the current decade, high-level fluoroquinolone resistance has emerged in south Asia and threatens to spread worldwide. Increasing reliance is now being placed on the activity of third generation cephalosporins and azithromycin, but resistance against these agents is developing. Carbapenems and tigecycline may be alternatives, although clinical data are sparse, and in some settings reversion to chloramphenicol and co-trimoxazole susceptibility is occurring. Therefore, older drugs may yet have a role in the treatment of S. Typhi infections. SUMMARY: Good surveillance, improved diagnostics, more prudent use of antimicrobials, and effective vaccines will all be critical to reducing the burden of disease caused by S. Typhi.
Authors: Amy T Y Yeung; Yoon Ha Choi; Amy H Y Lee; Christine Hale; Hannes Ponstingl; Derek Pickard; David Goulding; Mark Thomas; Erin Gill; Jong Kyoung Kim; Allan Bradley; Robert E W Hancock; Gordon Dougan Journal: mBio Date: 2019-10-08 Impact factor: 7.867
Authors: Christopher T Williams; Patrick Musicha; Nicholas A Feasey; Emily R Adams; Thomas Edwards Journal: J Antimicrob Chemother Date: 2019-05-01 Impact factor: 5.790
Authors: Narcisa Muresu; Giovanni Sotgiu; Bianca Maria Are; Andrea Cossu; Clementina Cocuzza; Marianna Martinelli; Sergio Babudieri; Riccardo Are; Marco Dettori; Antonio Azara; Laura Saderi; Andrea Piana Journal: Int J Environ Res Public Health Date: 2020-01-18 Impact factor: 3.390